Robotics industry vet and former Stryker Corporation senior executive Chris Fronk is joining Fremont, California-based THINK Surgical, Inc. as its new Vice President of U.S. Sales.
Chris Fronk Is THINK Surgical’s New VP of U.S. Sales
1 min read Premium comments
Secondary#thinksurgical#chrisfronk
Fronk has nearly 20 years of orthopedic sales experience. Most recently he worked for Redwood City, California-based Auris Health, Inc., a robotic medical company.
Prior to Auris Health, Fronk had a notable 17-year career at Stryker. During his time at Stryker, he won multiple sales awards in robotics, neuro, spine, ENT, orthopedic procedures, oncology procedures, traumatic procedures, and intra-operative 3D imaging. Fronk spent his last two years with Stryker as the key account manager for MAKO surgical robotics technology.
THINK Surgical President and CEO Stuart Simpson commented, “We are delighted that Chris [Fronk] has agreed to join our commercial leadership team.”
Simpson continued, “He has all the experience and skills necessary to work closely with our implant partner sales organizations and to identify and realize opportunities to start robotic surgery programs where implant freedom of choice is important to the customer. Chris [Fronk] is joining our team at an important time as we begin our commercialization phase at THINK. We look forward to seeing him work closely with the other members of the commercial leadership team as they build successful robot programs with customers across the country.”
THINK Surgical is a medical device and technology company with a focus on active robotics for orthopedic surgery. Fronk will utilize his nearly 20 years of sales experience to lead the commercialization of THINK Surgical’s robotic surgical platform.
Fronk expressed excitement about joining THINK Surgical saying, “I am excited to take on this role at THINK Surgical.”
Fronk continued, “THINK’s industry leading active robot technology combined with an open library of implants from different manufacturers represents the next level of offering for the orthopedic customer looking to start a successful robotic surgery program.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.